v3.26.3
CONVERTIBLE NOTES
9 Months Ended
Sep. 30, 2026
Convertible Notes Payable [Abstract]  
CONVERTIBLE NOTES
NOTE 9: CONVERTIBLE NOTES 

 

a. On November 14, 2025, the Company entered into a Secured Promissory Note (the “Original Note”) with Oramed in the principal amount of $3.0 million.

 

In February and March 2026, the Company entered into additional Secured Promissory Notes (the “Additional Notes”) with Oramed, pursuant to which the Company issued non-convertible secured promissory notes in the aggregate principal amount of $1.025 million. The Additional Notes are secured by a lien on the Company’s cash, accrue interest at a rate of 24% per annum, and mature on the earlier of August 12, 2026, or the failure to obtain shareholder approval of the transactions contemplated by the Securities Purchase Agreement dated January 12, 2026, by and among the Company, Oramed and certain investors (the “Securities Purchase Agreement”), and the SPA.

 

On March 25, 2026, pursuant to the Securities Purchase Agreement, the Company issued convertible notes (the “New Notes”) and freestanding warrants to Oramed and Creative Value Capital. Under the terms of the Original Note, if a subsequent financing involving convertible notes was consummated, the Original Note, including accrued and unpaid interest, would automatically convert into the New Notes upon consummation of such financing. In addition, under the terms of the Additional Notes, Oramed had the option to convert the Additional Notes into the New Notes. In connection with the March 25, 2026 financing, the Original Note and the Additional Notes were exchanged for New Notes. As such, the Company issued the New Notes in an aggregate principal amount of $10 million and 1,851,851 freestanding warrants with an exercise price of $5.4 per share. In addition, pursuant to the terms of the agreement, the Company may issue up to an additional $10 million principal amount of New Notes, convertible on substantially the same terms as the existing New Notes, upon the achievement of certain specified milestones and subject to the applicable conditions set forth in the Securities Purchase Agreement. Net cash proceeds received by the Company were approximately $5.4 million after giving effect to the exchange of the Original Note and the Additional Notes into the New Notes. The New Notes provide for a secured term loan in an aggregate principal amount of $10.0 million. The loan bears interest at the rate of 8% per annum and matures on March 25, 2029. The New Notes are convertible into 1,851,851 ordinary shares at a conversion price of $5.4 per share. The New Notes are secured by a lien on the Company’s cash and contain representations, covenants, and events of default. As of September 30, 2026, the Company was in compliance with all covenants.

 

The Company concluded that the warrants and the New Notes were freestanding financial instruments. The warrants were classified as liabilities, measured at fair value through earnings as the warrants were not indexed to the Company’s own stock. The Company also concluded that the conversion feature met the definition of a derivative and should be bifurcated from the debt host liability. As such, the Company recognized the warrants and the embedded derivative liability at fair value, with the remaining proceeds allocated to the debt host. The debt host was subsequently measured using the effective interest method. The Company derecognized the Original Note and the Additional Notes in connection with the exchange of such notes for the New Notes.

 

On June 30, 2026, the Company entered into the Amended and Restated Note and Warrant Documents. The amended agreements, among other things, provide for pari passu treatment of the Company’s outstanding senior secured convertible notes, revise certain contingent redemption provisions and modify certain beneficial ownership limitation provisions. These amendments also resulted in changes to the accounting classification of certain warrants and embedded conversion features, as described below.

 

Upon execution of the amended agreements, the Company remeasured the warrant liability and embedded derivative liability to fair value and reassessed their classification. The Company concluded that the warrants and the embedded conversion feature met the criteria for equity classification. Accordingly, the warrant liability and embedded derivative liability were reclassified to equity.

 

As of September 30, 2026, the carrying amount of the debt host was $4,882 thousand.

 

For the three and nine months ended September 30, 2026, the Company recognized total interest expense of $450 thousand and $1,742 thousand, respectively, related to the Original Note, the Additional Notes, and the New Notes.

 

b. On July 6, 2026, pursuant to a securities purchase agreement dated June 30, 2026, the Company issued $5.6 million of senior secured convertible notes (the “July Notes”) and accompanying freestanding warrants to purchase 1,033,331 ordinary shares. The July Notes bear interest at 8% per annum, mature three years after issuance and have an initial conversion price of $5.40 per ordinary share. The warrants have an initial exercise price of $5.40 per share and a five-year term. The agreement provides for an additional $5.6 million of notes and warrants, subject to contingent closing conditions including unit sales and share price targets.

 

The Company classified the warrants as liabilities and bifurcated the embedded conversion feature from the debt host. The warrant and embedded derivative liabilities were initially recognized at fair value, with the residual proceeds assigned to the debt host. Subsequently, both liabilities are remeasured at fair value through financial expense (income), net, while the debt host is measured at amortized cost using the effective interest method.

 

As of September 30, 2026, the carrying amount of the debt host of the July Notes was $17 thousand.

 

For the three months ended September 30, 2026, the Company recognized total interest expense of $7 thousand, related to the July Notes.